Explore the Agenda
8:00 am Check-In & Coffee
Grab a coffee and build upon relationships from day one in the hour before the conference begins
8:50 am Chair’s Opening Remarks
Measuring What Matters: Redefining Biomarkers & Endpoints for Treg Therapeutic Success
9:00 am Panel Discussion: Unearthing Strategies to Define & Measure Treg Modulation
- Defining effective Treg modulation to develop a standardized measurement of efficacy beyond the number of Tregs
- Evaluating genomic screening, cytokine measurement, Treg biology and tissue samples to identify the most effective strategy to measure Treg efficacy
- Highlighting the endpoint and efficacy criteria required for regulatory approval
- Discussing the translatability of preclinical mouse model biomarkers to patients
10:00 am Leveraging Big Data to Discover Novel Treg Biomarkers
- Exploring the methodology to apply big data strategies to uncover and validate biomarkers that track Treg expansion, stability, and therapeutic response
- Leveraging successes in big data analyses in the context of T-cell therapies for cancer to demonstrate the possibilities in Treg research
- Explore lineage tracing and spatial omics to identify Treg markers beyond traditional analyses
- Overview of methodology, sample types, and assays for correlative studies in Treg cell therapy trials
10:30 am Morning Break & Networking
Redefining Autoimmune Skin Disease Treatment with Treg Innovations in Atopic Dermatitis
11:30 am Keynote Presentation: Unraveling Targeted Treg Therapies for Autoimmune Diseases in the Skin
- Understanding the pathogenesis of autoimmune diseases in the skin to identify and target disease-driving mechanisms with Treg therapies
- Highlighting groundbreaking TRex Biology data
12:00 pm Driving Durable Relief in Atopic Dermatitis with Nektar’s REZPEG IL-2 Platform
- Showcasing the unique mechanism of Nektar’s REZPEG IL-2 platform and why it is effective in modulating immune balance
- Highlighting long-term maintenance data from the REZOLVE-AD study to demonstrate sustained efficacy and patient benefit
- Exploring how REZPEG can redefine therapeutic expectations for chronic atopic dermatitis management
12:30 pm Lunch Break & Networking
Unlocking CNS Access & Precision Treg Modulation to Transform Neurodegenerative Disease Therapy
1:30 pm Enhancing Tregs to Potentially Halt ALS Progression & Unlock new Neurodegenerative Treatment Paths
- Stimulating regulatory T cells to counter immune dysregulation and address a core driver of ALS disease progression
- Providing data supporting Coya's combination of Low Dose IL-2 + CTLA4-Ig to potentially halt ALS disease progression
- Exploring clinical trial design towards potential FDA approval
Defining Clinical Success in Treg Therapies from Indication & Patient Selection to Commercial Outcomes
1:30 pm Chair’s Closing Remarks & End of the 8th Treg-Directed Therapies Summit
2:00 pm The Current Treg Landscape for Autoimmune Diseases, Recent Deals & Emerging Companies
- Examine how Treg-directed therapies are reshaping treatment of autoimmune diseases
- Survey the leading Treg clinical trials testing immune tolerance in the clinic
- Highlight recent deals and the key players driving the Treg therapeutic landscape
2:30 pm A Novel Therapeutic Approach to Induce and Expand Tregs to Restore Immune Balance
Key Discussion Points:
- Innovative engineering of CUE-401 enables dual agonism of IL-2 and TGF-β for the induction of regulatory T cells
- First-in-class CUE-401 mechanism is differentiated from other classes of Treg-directed therapies
- Translational studies support broad therapeutic opportunities across diverse indications
3:00 pm Advancing Non-Cell Therapy Innovations to Combat Autoimmune & Inflammatory Diseases
- Highlighting apoptosis driven immune tolerance key signaling pathways
- Discussing supporting preclinical and mechanistic studies that inform trial design
- Reviewing clinical trial data in celiac disease and primary biliary cholangit